Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Med Oncol. 2012 Sep;29(3):2095-101. doi: 10.1007/s12032-012-0251-7. Epub 2012 May 22.

Abstract

This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or all-trans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Abnormal Karyotype
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Chromosome Aberrations*
  • Chromosomes, Human, Pair 15*
  • Chromosomes, Human, Pair 17*
  • Disease-Free Survival
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Leukemia, Promyelocytic, Acute / genetics*
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Tretinoin / therapeutic use
  • Young Adult

Substances

  • Antineoplastic Agents
  • Tretinoin